bioMerieux (OTCMKTS:BMXMF) Shares Gap Up - What's Next?

Key Points

• Gapped up pre-market to $82.91 from a $77.38 close and last traded around $82.75 on very light volume (105 shares), but remains well below its 50‑day and 200‑day moving averages (~$107 and $118).
• Brokerages have grown cautious—Deutsche Bank cut to "Hold", BNP Paribas Exane to "Neutral" and Zacks to "Hold", leaving a consensus rating of Hold (four analysts).
• bioMérieux is a global leader in in vitro diagnostics and shows healthy liquidity and low leverage, with a current ratio of 2.39, quick ratio of 1.48 and debt‑to‑equity of 0.08.

bioMerieux (OTCMKTS:BMXMF - Get Free Report) gapped up prior to trading on Friday . The stock had previously closed at $77.38, but opened at $82.91. bioMerieux shares last traded at $82.75, with a volume of 105 shares traded.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on BMXMF. Deutsche Bank Aktiengesellschaft cut shares of bioMerieux from a "buy" rating to a "hold" rating in a report on Friday, April 24th. Zacks Research raised shares of bioMerieux to a "hold" rating in a report on Tuesday. Finally, BNP Paribas Exane cut shares of bioMerieux to a "neutral" rating in a report on Wednesday, January 28th. Four analysts have rated the stock with a Hold rating, According to data from MarketBeat, the company currently has a consensus rating of "Hold".

bioMerieux Trading Up 0.4%

The stock has a fifty day moving average price of $107.39 and a two-hundred day moving average price of $118.16. The company has a current ratio of 2.39, a quick ratio of 1.48 and a debt-to-equity ratio of 0.08.

bioMerieux Company Profile

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company's product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.